We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Proteros and CHDI Establish Discovery Services Collaboration to Address Huntington’s Disease

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Proteros Biostructures GmbH has announced that it has entered into a service agreement with CHDI Foundation, Inc. (CHDI), under which Proteros will provide structure-based drug discovery services to CHDI.

Proteros will apply its integrated discovery platform including proprietary X-ray crystallography tools to help CHDI in its mission to develop therapeutics that slow the progression of Huntington’s disease (HD).

Cony D’Cruz Chief Business Officer and President Proteros US, Inc. stated, “CHDI has been at the forefront of using a best-in-class network to assist in developing therapies for HD. We welcome the opportunity for Proteros to contribute to this effort.”